Literature DB >> 22670043

An outbreak of Shiga toxin-producing Escherichia coli O104:H4 hemolytic uremic syndrome in Germany: presentation and short-term outcome in children.

Sebastian Loos1, Thurid Ahlenstiel, Brigitta Kranz, Hagen Staude, Lars Pape, Christoph Härtel, Udo Vester, Laura Buchtala, Kerstin Benz, Bernd Hoppe, Ortraud Beringer, Martin Krause, Dominik Müller, Martin Pohl, Johanna Lemke, Georg Hillebrand, Martin Kreuzer, Jens König, Marianne Wigger, Martin Konrad, Dieter Haffner, Jun Oh, Markus J Kemper.   

Abstract

BACKGROUND: In May and June 2011 the largest known outbreak of hemolytic uremic syndrome (HUS) occurred in northern Germany. Because, quite unusually, a large number of adults was affected and the causative Escherichia coli strain, serotype O104:H4, showed an atypical virulence factor pattern, it was speculated that this outbreak was associated with an aggressive course and an unfavorable prognosis also in children.
METHODS: Retrospective analysis of medical records of 90 children and comparison to previous outbreak and sporadic case series.
RESULTS: Median age was unusually high (11.5 years) compared with that in historical series. Only 1 patient (1.1%) died in the acute phase. Most patients (67/90 [74%]) received supportive care only. Renal replacement therapy was required in 64 of 90 (71%) of the children. Neurological complications, mainly seizures and altered mental stage, were present in 23 of 90 (26%) patients. Ten patients received plasmapheresis, 6 eculizumab, and 7 a combination of both. After a median follow-up of 4 months, renal function normalized in 85 of 90 (94%) patients, whereas 3 patients had chronic kidney disease stage 3 or 4, and 1 patient (1.1%) still requires dialysis. Complete neurological recovery occurred in 18 of 23 patients. Mild to moderate and major residual neurological changes were present in 3 patients and 1 patient, respectively, although all patients were still improving.
CONCLUSIONS: E. coli O104:H4 caused the largest HUS outbreak in children reported in detail to date and most patients received supportive treatment only. Initial morbidity, as well as short-term outcome, due to this pathogen, is comparable to previous pediatric series of Shiga toxin-producing E. coli HUS.

Entities:  

Mesh:

Year:  2012        PMID: 22670043     DOI: 10.1093/cid/cis531

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  46 in total

1.  Severe, persistent neurotoxicity after transplant-associated thrombotic microangiopathy in a pediatric patient despite treatment with eculizumab.

Authors:  Michelle Schoettler; Christine Duncan; Leslie Lehmann
Journal:  Pediatr Transplant       Date:  2019-03-03

2.  Diffusion-weighted imaging of the kidneys in haemolytic uraemic syndrome.

Authors:  Jochen Herrmann; Ulrich Wenzel; Stephanie Galler; Bjoern P Schoennagel; Jasmin D Busch; Magdalini Tozakidou; Kay U Petersen; Michaela Joekel; Peter Bannas; Jin Yamamura; Michael Groth; Gerhard Adam; Christian R Habermann
Journal:  Eur Radiol       Date:  2017-05-12       Impact factor: 5.315

3.  A simple prognostic index for Shigatoxin-related hemolytic uremic syndrome at onset: data from the ItalKid-HUS network.

Authors:  Gianluigi Ardissino; Francesca Tel; Sara Testa; Fabio Paglialonga; Selena Longhi; Laura Martelli; Silvia Consolo; Damiano Picicco; Antonella Dodaro; Laura Daprai; Rosaria Colombo; Milena Arghittu; Michela Perrone; Giovanna Chidini; Stefano Scalia Catenacci; Isabella Cropanese; Dario Consonni
Journal:  Eur J Pediatr       Date:  2018-08-10       Impact factor: 3.183

4.  Eculizumab treatment in severe pediatric STEC-HUS: a multicenter retrospective study.

Authors:  Lucas Percheron; Raluca Gramada; Stéphanie Tellier; Remi Salomon; Jérôme Harambat; Brigitte Llanas; Marc Fila; Emma Allain-Launay; Anne-Laure Lapeyraque; Valerie Leroy; Anne-Laure Adra; Etienne Bérard; Guylhène Bourdat-Michel; Hassid Chehade; Philippe Eckart; Elodie Merieau; Christine Piètrement; Anne-Laure Sellier-Leclerc; Véronique Frémeaux-Bacchi; Chloe Dimeglio; Arnaud Garnier
Journal:  Pediatr Nephrol       Date:  2018-03-23       Impact factor: 3.714

Review 5.  Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence.

Authors:  Werner Keenswijk; Ann Raes; Johan Vande Walle
Journal:  Eur J Pediatr       Date:  2017-12-29       Impact factor: 3.183

6.  Enterohemorrhagic colitis with disseminated intravascular coagulation.

Authors:  Gregory Taroyan; Andrew L Juergens
Journal:  Proc (Bayl Univ Med Cent)       Date:  2018-05-14

7.  Gram-negative organisms in peritoneal dialysis peritonitis: an early indication for surgery in patients with haemolytic uraemic syndrome?

Authors:  Rachel Harwood; David Wilkinson; Shweta Ramkumar; Gillian Humphrey
Journal:  Pediatr Surg Int       Date:  2015-11-17       Impact factor: 1.827

8.  Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement.

Authors:  Monica Locatelli; Simona Buelli; Anna Pezzotta; Daniela Corna; Luca Perico; Susanna Tomasoni; Daniela Rottoli; Paola Rizzo; Debora Conti; Joshua M Thurman; Giuseppe Remuzzi; Carlamaria Zoja; Marina Morigi
Journal:  J Am Soc Nephrol       Date:  2014-02-27       Impact factor: 10.121

Review 9.  HUS and TTP in Children.

Authors:  Howard Trachtman
Journal:  Pediatr Clin North Am       Date:  2013-12       Impact factor: 3.278

Review 10.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome.

Authors:  Joann M Spinale; Rebecca L Ruebner; Lawrence Copelovitch; Bernard S Kaplan
Journal:  Pediatr Nephrol       Date:  2013-01-04       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.